[go: up one dir, main page]

ECSP14002014A - N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas - Google Patents

N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas

Info

Publication number
ECSP14002014A
ECSP14002014A ECIEPI20142014A ECPI201402014A ECSP14002014A EC SP14002014 A ECSP14002014 A EC SP14002014A EC IEPI20142014 A ECIEPI20142014 A EC IEPI20142014A EC PI201402014 A ECPI201402014 A EC PI201402014A EC SP14002014 A ECSP14002014 A EC SP14002014A
Authority
EC
Ecuador
Prior art keywords
phenyl
amino
treatment
methylalaninamide
sulfonil
Prior art date
Application number
ECIEPI20142014A
Other languages
English (en)
Inventor
Lager Joanne
Decillis Arthur
Original Assignee
Paris Dakar
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP14002014(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Paris Dakar, Sanofi Sa filed Critical Paris Dakar
Publication of ECSP14002014A publication Critical patent/ECSP14002014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan métodos para el tratamiento de una neoplasia linfoproliferativa a un paciente en necesidad de dicho tratamiento, comprendiendo la administración al paciente de una cantidad efectiva del compuesto A como se describe aquí.
ECIEPI20142014A 2011-11-01 2014-05-26 N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas ECSP14002014A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553990P 2011-11-01 2011-11-01
US201161568189P 2011-12-08 2011-12-08
PCT/US2012/062999 WO2013067141A1 (en) 2011-11-01 2012-11-01 N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies

Publications (1)

Publication Number Publication Date
ECSP14002014A true ECSP14002014A (es) 2015-11-30

Family

ID=47295148

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20142014A ECSP14002014A (es) 2011-11-01 2014-05-26 N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas

Country Status (22)

Country Link
US (2) US20140303172A1 (es)
EP (1) EP2773353B1 (es)
JP (1) JP6013498B2 (es)
KR (1) KR20140096083A (es)
CN (2) CN104302294A (es)
AU (2) AU2012332486A1 (es)
BR (1) BR112014010492A2 (es)
CA (1) CA2854159A1 (es)
CL (1) CL2014001138A1 (es)
CR (1) CR20140253A (es)
DO (1) DOP2014000092A (es)
EA (1) EA201490905A1 (es)
EC (1) ECSP14002014A (es)
HK (1) HK1201480A1 (es)
IL (1) IL232398A0 (es)
MX (1) MX2014005249A (es)
NI (1) NI201400037A (es)
PE (1) PE20141794A1 (es)
PH (1) PH12014500973A1 (es)
SG (1) SG11201401961UA (es)
WO (1) WO2013067141A1 (es)
ZA (1) ZA201403258B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500973A1 (en) 2011-11-01 2014-06-16 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
AR092501A1 (es) * 2012-09-13 2015-04-22 Sanofi Sa Compuestos cristalinos
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO2007044813A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
HRP20140975T1 (hr) * 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
JP5480503B2 (ja) 2005-10-07 2014-04-23 エクセリクシス， インク． ＰＩ３Ｋαのピリドピリミジノン型阻害剤
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
UA100979C2 (ru) 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
WO2008127678A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
WO2008127712A1 (en) 2007-04-11 2008-10-23 Exelixis, Inc. Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
PT2139483E (pt) * 2007-04-11 2013-12-27 Exelixis Inc Terapias de combinação que compreendem um inibidor de quinoxalina de pi3k-alfa para utilizar no tratamento de cancro
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP2011510010A (ja) * 2008-01-15 2011-03-31 ワイス・エルエルシー ３Ｈ−［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成
UY32153A (es) 2008-09-30 2011-04-29 Exelixis Inc Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CA2755554C (en) * 2009-04-17 2013-09-24 Wyeth Llc Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2012527474A (ja) 2009-05-22 2012-11-08 エクセリクシス， インク． 増殖性疾患に対するベンゾキサゼピンベースのｐｉ３ｋ／ｍｔ０ｒ阻害剤
JP2012528165A (ja) 2009-05-26 2012-11-12 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾキサゼピンならびにそれらの使用および製造方法
AR080151A1 (es) 2010-02-09 2012-03-14 Exelixis Inc Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
UY33498A (es) * 2010-07-09 2013-01-03 Sanofi Aventis Combinaciones de inhibidores de quinasas para el tratamiento de cancer
AU2011302124B2 (en) 2010-09-14 2016-03-17 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
CA2812089C (en) 2010-09-14 2020-02-18 Exelixis Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
EP2444084A1 (en) * 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012065057A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US20140107100A1 (en) 2010-11-24 2014-04-17 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
EP2643319A1 (en) 2010-11-24 2013-10-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
BR112013012961A2 (pt) 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
WO2012071509A2 (en) 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
US20140073628A1 (en) 2010-11-24 2014-03-13 Kenneth D. Rice Benzoxazepines asn inhibitors of p13k/m tor and methods of their use and manufacture
MX2013012486A (es) 2011-04-29 2014-05-28 Exelixis Inc Metodo para tratar linfoma usando inhibidores de piridopirimidinona de fosfonio sitol 3-cinasa/diana de rapalamina en celulas de mamifero (pi3k/mtor).
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
PH12014500973A1 (en) 2011-11-01 2014-06-16 Exelixis Inc Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
US10035790B2 (en) 2012-10-19 2018-07-31 Exelixis, Inc. RORγ modulators

Also Published As

Publication number Publication date
CN104302294A (zh) 2015-01-21
EA201490905A1 (ru) 2014-11-28
CL2014001138A1 (es) 2014-08-01
JP2014532709A (ja) 2014-12-08
MX2014005249A (es) 2015-03-05
EP2773353A1 (en) 2014-09-10
HK1201480A1 (en) 2015-09-04
ZA201403258B (en) 2015-11-25
IL232398A0 (en) 2014-06-30
CN107375289A (zh) 2017-11-24
CR20140253A (es) 2014-10-28
US20140303172A1 (en) 2014-10-09
EP2773353B1 (en) 2018-09-05
US20170296529A1 (en) 2017-10-19
AU2017219131A1 (en) 2017-09-28
WO2013067141A1 (en) 2013-05-10
KR20140096083A (ko) 2014-08-04
AU2012332486A1 (en) 2014-06-19
PE20141794A1 (es) 2014-12-17
BR112014010492A2 (pt) 2017-04-25
US10328069B2 (en) 2019-06-25
PH12014500973A1 (en) 2014-06-16
NI201400037A (es) 2014-12-22
CA2854159A1 (en) 2013-05-10
JP6013498B2 (ja) 2016-10-25
DOP2014000092A (es) 2015-02-15
SG11201401961UA (en) 2014-05-29

Similar Documents

Publication Publication Date Title
ECSP12011799A (es) Compuestos de espiropiperidina y uso farmacéutico de los mismos
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
EA201290919A1 (ru) Индазольные соединения и их применение
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
GT201300213A (es) Derivados de fluoro-piridinona útiles como agentes antibacterianos
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
EA201591024A1 (ru) Димерные соединения
UA114417C2 (uk) Інгібітори iap
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
CR20120654A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
EA201590656A1 (ru) Азаиндолины
EA201300092A1 (ru) Замещенные производные оксадиазола
ECSP14002014A (es) N-(3-{[(3-{[2-cloro-5-(metoxi) fenil] amino} quinoxalin-2-il) amino] sulfonil} fenil)-2-metilalaninamida como inhibidor de fosfatidilinositol 3-quinasa para el tratamiento de neoplasias linfoproliferativas
EA201590696A1 (ru) Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2
EA201491581A1 (ru) Везикулярные композиции
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
AR098134A1 (es) Compuestos de urea